---
title: "Editas Medicine names Patrick Ellinor to board, Elliott Levy to step down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294872207.md"
description: "Editas Medicine has appointed Patrick T. Ellinor to its board of directors, effective August 6, 2026. Ellinor serves as executive director of the Mass General Brigham Heart and Vascular Institute and directs the Cardiovascular Disease Initiative at the Broad Institute. Concurrently, board member Elliott Levy is stepping down from his role as an independent director."
datetime: "2026-08-04T21:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294872207.md)
  - [en](https://longbridge.com/en/news/294872207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294872207.md)
generator: "portal-rs"
---

# Editas Medicine names Patrick Ellinor to board, Elliott Levy to step down

-   Editas Medicine appointed Patrick T. Ellinor to its board, effective Aug. 6, 2026. \* Ellinor is executive director of the Mass General Brigham Heart and Vascular Institute. \* He also directs the Cardiovascular Disease Initiative at the Broad Institute of MIT and Harvard. \* Board member Elliott Levy will step down, ending his role as an independent director. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041615PRIMZONEFULLFEED9803687) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EDIT.US](https://longbridge.com/en/quote/EDIT.US.md)

## Related News & Research

- [Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement](https://longbridge.com/en/news/295279253.md)
- [Heartflow FFRCT trial data show 44% drop in unnecessary invasive heart catheterizations](https://longbridge.com/en/news/297276738.md)
- [VivoSim Labs plans rat liver model expansion for NAMkind platform](https://longbridge.com/en/news/297649874.md)
- [Moleculin Biotech highlights interim Phase 3 AML data for annamycin showing 36% CR, 54% CRc in pooled arms](https://longbridge.com/en/news/297668239.md)
- [Autonomix Medical says two transvascular technology abstracts accepted for CIRSE 2026 posters](https://longbridge.com/en/news/297652835.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**